What is the drug of choice for PDA?

Preferred Medications for Treating Patent Ductus Arteriosus in Newborns

Patent Ductus Arteriosus (PDA) is a common condition in premature infants, where the ductus arteriosus— a blood vessel that connects two major arteries in the fetal heart—fails to close after birth. If left untreated, it can lead to complications such as heart failure or respiratory distress. The good news is that effective medical treatments are available, especially when administered early.

IV indomethacin has long been the drug of choice for closing a PDA in neonates, particularly when given within the first 10 to 14 days of life. This window is critical because the ductus tends to become less responsive to medication as time passes. Indomethacin works by inhibiting prostaglandin synthesis, which plays a key role in keeping the ductus open during fetal development. By blocking this pathway, the medication promotes closure of the vessel.

In recent years, IV ibuprofen has emerged as a viable alternative, offering similar efficacy with potentially fewer side effects—especially concerning kidney function and platelet inhibition. Some neonatal intensive care units now prefer ibuprofen due to its more favorable safety profile, although both drugs are widely used depending on institutional protocols and patient factors.

While surgical ligation remains an option for cases unresponsive to medication, pharmacological closure remains the first-line approach in eligible preterm infants. Timing is essential: early diagnosis and treatment within the first two weeks significantly improve success rates. Ultimately, the choice between indomethacin and ibuprofen depends on the baby’s clinical condition, gestational age, and individual risk factors.